Docoh
Loading...

SANA Sana Biotechnology

News

From Benzinga Pro
Stocks That Hit 52-Week Lows On Wednesday
19 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's morning trading, 400 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
14 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Friday's session, 445 companies made new 52-week lows.
The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
11 Jan 22
Biotech, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies
11 Jan 22
Biotech, News, Health Care, Contracts, General
Sana Biotechnology Inc (NASDAQ: SANA) has
Sana Biotechnology Obtains Exclusive License From National Institutes Of Health For CD22 CAR Construct
11 Jan 22
Biotech, General
License will enable Sana's in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
Stocks Hitting New 52-Week Lows Today
3 Jan 22
News, Intraday Update, Markets, Movers, Trading Ideas
On Monday morning, 60 companies achieved new lows for the year.
Sana Biotechnology Announced Hypoimmune Car T Cells Evade Both Innate And Adaptive Immune Systems In Murine Models, Even In Animals With Pre-existing Immunity to Car T Cells at ASH 2021
12 Dec 21
News, Events
Sana Biotechnology, Inc.
Sana Biotechnology Q3 EPS $(0.46) Up From $(3.76) YoY
8 Nov 21
Earnings, News
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.46) per share. This is a 87.77 percent increase over losses of $(3.76) per share from the same period last year.

Press releases

From Benzinga Pro
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
11 Jan 22
Press Releases
License will enable Sana's in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies SEATTLE, Jan. 11,
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
10 Jan 22
Press Releases
SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
4 Jan 22
Press Releases
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
17 Dec 21
Press Releases
BOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
12 Dec 21
News, Press Releases
Hypoimmune CAR T cells evade both innate and adaptive immune systems in murine models, even in animals with pre-existing immunity to CAR T cells CD8- and CD4-targeted fusosomes generated functional CAR T cells in vivo,
Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors
8 Dec 21
Penny Stocks, Small Cap, Press Releases
Estepan brings to Cellarity's BOD deep experience and expertise in all aspects of finance, corporate strategy, investor relations, and business development, and a dedication to directly improving patient lives through innovation in medicine
Generate Biomedicines Announces First External Equity Raise of $370 Million to Advance Its Drug Generation Platform
18 Nov 21
Penny Stocks, Small Cap, Press Releases
- Generate is harnessing the power of data and machine learning at scale to program biology, dramatically improve the human condition, and democratize biotherapeutics
Flagship Pioneering Announces Appointment of Justine Levin-Allerhand as Senior Partner, Corporate Development
15 Nov 21
Press Releases
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that Justine Levin-Allerhand, Ph.D., has joined the company in a newly created role as Senior
Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates
8 Nov 21
Earnings, Press Releases
Announced license agreement for Beam's CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Sana
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
4 Nov 21
Biotech, News, Press Releases, General
SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four
Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship's Pioneering Medicines to Treat Cystic Fibrosis
3 Nov 21
Penny Stocks, Small Cap, Press Releases
Tessera's Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their Entirety